These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 9620075

  • 1. A therapeutic vaccine that reduces recurrent herpes simplex virus type 1 corneal disease.
    Nesburn AB, Burke RL, Ghiasi H, Slanina SM, Wechsler SL.
    Invest Ophthalmol Vis Sci; 1998 Jun; 39(7):1163-70. PubMed ID: 9620075
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Therapeutic immunization with a mixture of herpes simplex virus 1 glycoprotein D-derived “asymptomatic” human CD8+ T-cell epitopes decreases spontaneous ocular shedding in latently infected HLA transgenic rabbits: association with low frequency of local PD-1+ TIM-3+ CD8+ exhausted T cells.
    Khan AA, Srivastava R, Chentoufi AA, Geertsema R, Thai NT, Dasgupta G, Osorio N, Kalantari M, Nesburn AB, Wechsler SL, BenMohamed L.
    J Virol; 2015 Jul; 89(13):6619-32. PubMed ID: 25878105
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of a recombinant glycoprotein D subunit vaccine on the development of primary and recurrent ocular infection with herpes simplex virus type 1 in mice.
    Keadle TL, Laycock KA, Miller JK, Hook KK, Fenoglio ED, Francotte M, Slaoui M, Stuart PM, Pepose JS.
    J Infect Dis; 1997 Aug; 176(2):331-8. PubMed ID: 9237697
    [Abstract] [Full Text] [Related]

  • 6. A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral Immunity.
    Royer DJ, Gurung HR, Jinkins JK, Geltz JJ, Wu JL, Halford WP, Carr DJJ.
    J Virol; 2016 Jun 01; 90(11):5514-5529. PubMed ID: 27030264
    [Abstract] [Full Text] [Related]

  • 7. Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits.
    Nesburn AB, Slanina S, Burke RL, Ghiasi H, Bahri S, Wechsler SL.
    J Virol; 1998 Oct 01; 72(10):7715-21. PubMed ID: 9733807
    [Abstract] [Full Text] [Related]

  • 8. Ocular safety and efficacy of an HSV-1 gD vaccine during primary and latent infection.
    Nesburn AB, Ghiasi H, Wechsler SL.
    Invest Ophthalmol Vis Sci; 1990 Aug 01; 31(8):1497-502. PubMed ID: 2167298
    [Abstract] [Full Text] [Related]

  • 9. Prior Corneal Scarification and Injection of Immune Serum are Not Required Before Ocular HSV-1 Infection for UV-B-Induced Virus Reactivation and Recurrent Herpetic Corneal Disease in Latently Infected Mice.
    BenMohamed L, Osorio N, Khan AA, Srivastava R, Huang L, Krochmal JJ, Garcia JM, Simpson JL, Wechsler SL.
    Curr Eye Res; 2016 Jun 01; 41(6):747-56. PubMed ID: 26398722
    [Abstract] [Full Text] [Related]

  • 10. Large Amounts of Reactivated Virus in Tears Precedes Recurrent Herpes Stromal Keratitis in Stressed Rabbits Latently Infected with Herpes Simplex Virus.
    Perng GC, Osorio N, Jiang X, Geertsema R, Hsiang C, Brown D, BenMohamed L, Wechsler SL.
    Curr Eye Res; 2016 Jun 01; 41(3):284-91. PubMed ID: 25859798
    [Abstract] [Full Text] [Related]

  • 11. HSV-1 migration in latently infected and naive rabbits after penetrating keratoplasty.
    Zheng X, Marquart ME, Loustch JM, Shah P, Sainz B, Ray A, O'Callaghan RJ, Kaufman HE, Hill JM.
    Invest Ophthalmol Vis Sci; 1999 Oct 01; 40(11):2490-7. PubMed ID: 10509641
    [Abstract] [Full Text] [Related]

  • 12. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs.
    Hoshino Y, Pesnicak L, Dowdell KC, Burbelo PD, Knipe DM, Straus SE, Cohen JI.
    J Infect Dis; 2009 Oct 01; 200(7):1088-95. PubMed ID: 19702506
    [Abstract] [Full Text] [Related]

  • 13. Blockade of PD-1 and LAG-3 Immune Checkpoints Combined with Vaccination Restores the Function of Antiviral Tissue-Resident CD8+ TRM Cells and Reduces Ocular Herpes Simplex Infection and Disease in HLA Transgenic Rabbits.
    Roy S, Coulon PG, Prakash S, Srivastava R, Geertsema R, Dhanushkodi N, Lam C, Nguyen V, Gorospe E, Nguyen AM, Salazar S, Alomari NI, Warsi WR, BenMohamed L.
    J Virol; 2019 Sep 15; 93(18):. PubMed ID: 31217250
    [Abstract] [Full Text] [Related]

  • 14. Reactivation and donor-host transmission of herpes simplex virus after corneal transplantation.
    Zheng X.
    Cornea; 2002 Oct 15; 21(7 Suppl):S90-3. PubMed ID: 12484706
    [Abstract] [Full Text] [Related]

  • 15. Protection against herpes simplex virus-induced eye disease after vaccination with seven individually expressed herpes simplex virus 1 glycoproteins.
    Ghiasi H, Bahri S, Nesburn AB, Wechsler SL.
    Invest Ophthalmol Vis Sci; 1995 Jun 15; 36(7):1352-60. PubMed ID: 7775113
    [Abstract] [Full Text] [Related]

  • 16. Human Asymptomatic Epitope Peptide/CXCL10-Based Prime/Pull Vaccine Induces Herpes Simplex Virus-Specific Gamma Interferon-Positive CD107+ CD8+ T Cells That Infiltrate the Corneas and Trigeminal Ganglia of Humanized HLA Transgenic Rabbits and Protect against Ocular Herpes Challenge.
    Khan AA, Srivastava R, Vahed H, Roy S, Walia SS, Kim GJ, Fouladi MA, Yamada T, Ly VT, Lam C, Lou A, Nguyen V, Boldbaatar U, Geertsema R, Fraser NW, BenMohamed L.
    J Virol; 2018 Aug 15; 92(16):. PubMed ID: 29899087
    [Abstract] [Full Text] [Related]

  • 17. Protection against recurrent ocular herpes simplex virus type 1 disease after therapeutic vaccination of latently infected mice.
    Richards CM, Case R, Hirst TR, Hill TJ, Williams NA.
    J Virol; 2003 Jun 15; 77(12):6692-9. PubMed ID: 12767989
    [Abstract] [Full Text] [Related]

  • 18. Reactivation of herpes virus after lamellar keratoplasty.
    Zheng X, Loutsch JM, Shimomura Y, Gebhardt BM, Hill JM, Kaufman HE.
    Jpn J Ophthalmol; 1999 Jun 15; 43(4):257-61. PubMed ID: 10482469
    [Abstract] [Full Text] [Related]

  • 19. Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection.
    Shlapobersky M, Marshak JO, Dong L, Huang ML, Wei Q, Chu A, Rolland A, Sullivan S, Koelle DM.
    J Gen Virol; 2012 Jun 15; 93(Pt 6):1305-1315. PubMed ID: 22398318
    [Abstract] [Full Text] [Related]

  • 20. The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes.
    Bernstein DI, Pullum DA, Cardin RD, Bravo FJ, Dixon DA, Kousoulas KG.
    Vaccine; 2019 Jan 03; 37(1):61-68. PubMed ID: 30471955
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.